2 completed, 2 withdrawn, 1 terminated. 3 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Finch Research and Development LLC.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) CP101, Placebo - Recurrent C. Difficile Infection | Phase 3 | Terminated | Finch Research and Development LLC. | 19 | 2021-11-15 | 2023-11-13 |
| Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) CP101, Placebo - Autism Spectrum Disorder, Autism | Phase 2 | Withdrawn | Finch Research and Development LLC. | 2020-05-01 | 2021-04-08 | |
| Pilot Study Using Oral Capsule FMT to Decolonize GI CRE Fecal Microbiota Transplantation - Enterobacteriaceae Infections, Fecal Microbiota Transplantation | Early Phase 1 | Withdrawn | University of California, Los Angeles | 2019-06-01 | 2019-10-23 | |
| Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection CP101 - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection | Phase 2 | Completed | Finch Research and Development LLC. | 132 | 2018-05-01 | 2022-08-30 |
| Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff Full Spectrum Microbiota, Placebo - Clostridium Difficile Infection Recurrence | Phase 2 | Completed | Finch Research and Development LLC. | 206 | 2017-05-08 | 2022-10-05 |
Clostridium Infections (3) · Diabetes Insipidus, Neurogenic (2) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Child Development Disorders, Pervasive (1) · Enterobacteriaceae Infections (1)
Fecal Microbiota Transplantation (1)
Canada (3) · United States (3)
Zachary Rubin, MD (1) · Zain Kassam, MD, MPH (1)